Advocacy groups are urging the U.S. Trade Representative (USTR) not to sanction South Africa, India, Ukraine, and Brazil for attempting to bypass Vertex Pharmaceuticals' patents on the high-cost cystic fibrosis drug Trikafta. The coalition argues that public health needs, addressed through potential compulsory licensing for cheaper generics, should supersede patent enforcement, citing high international prices. For more details, visit STAT News .